LUNG CANCER

In this article, Priyanka Bhateja, MD, and Neelesh Sharma, MD, PhD review the completed trials and ongoing clinical development of pembrolizumab in NSCLC.

Tremelimumab as a monotherapy in both the second- and third-line treatment failed to boost overall survival (OS) compared with placebo for patients with unresectable malignant mesothelioma.

Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.

Everolimus (Afinitor) has received FDA approval for adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal (GI) or lung neuroendocrine tumors (NET), based on findings from the phase III RADIANT-4 trial.

In the study, the bavituximab combination showed OS data similar to expectations while patients in the docetaxel-alone arm "dramatically outperformed OS expectations," according to Peregrine Pharmaceuticals.

Despite its initial running start, the continuing development of immunotherapies in the field of non-small cell lung cancer (NSCLC) won't be slowing down anytime soon, according to Naiyer Rizvi, MD.

Patients with advanced non-small cell lung cancer receiving the combination checkpoint blockade with the PD-L1 inhibitor durvalumab and the anti-CTLA-4 agent tremelimumab had a response rate of 23%, according to phase Ib data from Study 006.

The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) advisory hearing for April 12 to review the new drug application for rociletinib, a treatment for metastatic EGFR T790-mutated non-small cell lung cancer.

Single-dose fosaprepitant dimeglumine (Emend for injection) in combination with antiemetic agents has been approved by the FDA for the preventing

With atezolizumab (MPDL3280A) showing great potential as a treatment for patients with non

Lorraine Pelosof, MD, PhD, assistant professor of Hematology and Oncology, UT Southwestern Medical Center, on the increasing proportion of non-smokers developing non-small cell lung cancer (NSCLC).

Eric Lim, MD, consultant thoracic surgeon, Royal Brompton Hospital, Senior lecturer in thoracic surgery and reader, Imperial College London, discusses the decline in smoking not correlating to the current amount of lung cancer diagnoses.

​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non

Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.

A study analysis tackles the ethical debate surrounding the impact of the increasing requirement for research biopsies on the participation of patients with advanced non-small lung cancer in clinical trials.

Marianne Davies, NP, discusses making patients' oncology team their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether it is an immune-related side effect, or an issue that can be dealt with by their primary care physician.

Researchers have identified a potential new biomarker for non-small cell lung cancer (NSCLC), which may help increase the efficacy of an emerging vaccine based on the MUC-1 antigen.

A team from the Scripps Research Institute and Bristol-Myers Squibb recently collaborated to collectively develop a method for complete chemical synthesis of antroquinonol and to test the biologic activity of the chemically synthesized product. Contrary to previous reports, the study reported minimal in vitro and in vivo antitumor activity of chemically synthesized antroquinonol A.

The success of the immunotherapies pembrolizumab and nivolumab for the treatment of non-small cell lung cancer (NSCLC), and the promising results in NSCLC for the investigational agent atezolizumab, have generated an interest in new combinations with other agents

Although FGFR pathway deregulation has been identified frequently in NSCLC, clinical activity of FGFR inhibitors has been considered disappointing and modest, at best, to date.

A recent study demonstrated that specimens from patients with lung cancer under the age of 50 years appear to be enriched with molecular alterations that are amenable to targeted treatment.

There are no differences in lung cancer incidence or mortality among women of different ethnic groups when adjusted for age, smoking, and other factors, according to an article recently published in the Journal of Clinical Oncology.

Non-small cell lung cancer with mutations in the KRAS gene may be associated with reduced activity of a key endocytic pathway and a mesenchymal phenotype, which may cause metastases.

Rex Chin-Wei Yung, MD, FCCP, discusses the value of teamwork in oncology, specifically lung cancer, and the importance of pulmonologists.

The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.